MSACL 2022 Abstract

Self-Classified Topic Area(s): Practical Training

Podium Presentation in Bonzai on Wednesday at 16:30 (Chair: TBA)

Clinically available. Transition Ratio Monitoring for the Masses
Russ Grant
Laboratory Corporation of America

Russell Grant, PhD (Presenter)
Labcorp

Presenter Bio: Dr. Grant earned a first-class honors degree in Industrial Chemistry from Cardiff University and a PhD in Chromatographic and Mass Spectrometric technologies from the University of Swansea, Wales, United Kingdom. He continued his scientific training in various industrial settings, which have included senior scientist at GSK, Principal scientist at Cohesive Technologies, Technical director at Eli Lilly, and Director of Mass Spectrometry at Esoterix Endocrinology. Dr Grant is currently the Vice President of Research and Development and co-discipline director for Mass spectrometry at Labcorp. Dr Grant has pioneered the use of direct injection technologies, chromatographic systems multiplexing, microsampling, utility of automation, and other new analytical platforms in direct patient care. His research goals are focused upon improvements in speed, sensitivity, and quality of liquid chromatography with tandem mass spectrometric (LC-MS/MS) analytical systems and assays. Dr Grant has been awarded 100 patents and received both the MSACL Distinguished contribution award and ASMS AL Yergey “Unsung Hero” Award in 2024 for his contributions to Clinical Diagnostics using Mass Spectrometry.

Abstract

Central to determining assay quality and results reporting apriori is the fundamental belief that one is selectively measuring the analyte of choice. The use of transition ratio monitoring, while somewhat known to many users of tandem mass spectrometry, still provides a multitude of discreet challenges in the development, use and interrogation of chromatographic data. Historical rules based review, driven by qualifier transition yield relative to the quantifier transition fails to provide the appropriate quality considerations based on meaningful data. This presentation will include an arc of developmental understanding, from initial assessments (including favoring selectivity over sensitivity), validation of ion ratio's (sample types and concentrations) and use of transition ratio's (multi-level, non-symmetrical and statistically based).

Take home "Pearls" include:
1. How to select appropriate transitions for use in transition ratio monitoring - including tools to enhance response function for low intensity transitions
2. How to improve the precision of Transition ratio's through scheduling and appropriate dwell times
3. How to design transition ratio tolerances to enhance medical utility and including when to ignore the qualifier transition.

Financial Disclosure

Description	Y/N	Source
Grants	no
Salary	yes	Laboratory Corporation of America
Board Member	no
Stock	yes	Laboratory Corporation of America
Expenses	no
IP Royalty	no

Planning to mention or discuss specific products or technology of the company(ies) listed above:
no